Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2...

Area of Science:

• Molecular Biology
• Virology
• Antiviral Therapy

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly evolves resistance to antibody therapies, necessitating new antiviral approaches.
• The emergence of variants like Omicron highlights the waning effectiveness of current treatments against evolving viruses.
• Long antisense RNAs (asRNAs) have shown promise in repressing viral gene expression, evading viral evolution.

Purpose of the Study:

• To develop a novel antiviral strategy using long antisense RNAs (asRNAs) to target SARS-CoV-2.
• To investigate the efficacy of delivering asRNAs via engineered extracellular vesicles (EVs) for antiviral therapy.
• To demonstrate a broadly applicable method for controlling viral expression independent of mutation.

Main Methods:

• Design and synthesis of a long asRNA targeting the SARS-CoV-2 RNA-dependent RNA polymerase gene.
• Encapsulation of the asRNA payload within engineered extracellular vesicles (EVs).
• In vitro assessment of EV-delivered asRNA's ability to repress SARS-CoV-2 replication.

Main Results:

• The study successfully engineered EVs to deliver functional asRNA payloads.
• EV-delivered asRNAs demonstrated significant repression of SARS-CoV-2 expression.
• This represents the first use of engineered EVs for delivering asRNA in antiviral therapy.

Conclusions:

• Extracellular vesicle-delivered asRNAs offer a potent and broadly applicable strategy against SARS-CoV-2 infection.
• This approach provides an effective means to control viral expression, circumventing viral resistance mechanisms.
• The findings establish a new paradigm for developing RNA-based antiviral therapies.